Evidence map›Paper›PMID 35630412›Full record

ArticleMicroorganisms2022

Evaluation of S1RBD-Specific IgG Antibody Responses following COVID-19 Vaccination in Healthcare Professionals in Cyprus: A Comparative Look between the Vaccines of Pfizer-BioNTech and AstraZeneca.

Elie Deeba, George Krashias, Astero Constantinou, Dana Koptides, Anastasia Lambrianides, Christina Christodoulou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elie DeebaDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-2273-8175
George KrashiasDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Astero ConstantinouDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Dana KoptidesDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Anastasia LambrianidesDepartment of Neuroimmunology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Christina ChristodoulouDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Cyprus Institute of Neurology and Genetics · CY

Funding

The Cyprus Institute of Neurology and Genetics 2020-80B
6 · The paper itself

Abstract

There is an ongoing effort to report data on SARS-CoV-2 antibodies in different individuals. Ninety-seven healthcare workers were enrolled in this study (Pfizer's BNT162b2,

Indexed as

IgG antibodySARS-CoV-2spike 1 receptor binding proteinvaccine

Identifiers

PMID35630412
PMCPMC9147250
OpenAlexW4229021965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.